GlaxoSmithKline
GSK
#191
Rank
$71.86 B
Marketcap
$35.10
Share price
0.17%
Change (1 day)
-19.07%
Change (1 year)

P/E ratio for GlaxoSmithKline (GSK)

P/E ratio as of March 2023 (TTM): 4.44

According to GlaxoSmithKline's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 4.43932. At the end of 2021 the company had a P/E ratio of 14.7.

P/E ratio history for GlaxoSmithKline from 2001 to 2022

PE ratio at the end of each year

Year P/E ratio Change
202114.745.85%
202010.1-35.71%
201915.7-0.75%
201815.8-55.39%
201735.5-44.04%
201663.4919.49%
20156.22-66.06%
201418.354.42%
201311.91.24%
201211.76.27%
201111.0

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
28.5 542.24%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
7.14 60.86%๐Ÿ‡บ๐Ÿ‡ธ USA
19.0 329.04%๐Ÿ‡ซ๐Ÿ‡ท France
18.4 314.86%๐Ÿ‡บ๐Ÿ‡ธ USA
64.7 1,357.81%๐Ÿ‡ฌ๐Ÿ‡ง UK
-4.13-193.08%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
4.23-4.83%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.